Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_1
1
25%
Ph phase_3
1
25%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Other(2)

Detailed Status

Completed2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (50.0%)
Phase 31 (50.0%)

Trials by Status

completed250%
unknown250%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

NCT04138277
completedphase_1

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

NCT02675465
unknown

Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease

NCT03865836
unknown

Expanded Access for ATB200/AT2221 for the Treatment of IOPD

NCT04327973

Clinical Trials (4)

Showing 4 of 4 trials
NCT04138277Phase 3

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

Completed
NCT02675465Phase 1

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

Completed
NCT03865836

Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease

Unknown
NCT04327973

Expanded Access for ATB200/AT2221 for the Treatment of IOPD

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4